Metamizol Kalceks (Metamizole Sodium Monohydrate)

• Metamizol Kalceks, a pyrazolone analgesic, is used for conditions involving acute pain, postoperative pain, fever, and visceral colic.
• Acute pain: provides rapid analgesia for severe short‑term pain.
• Post‑operative pain: reduces pain after surgical procedures.
• Fever: lowers elevated body temperature in febrile states.
• Colic and visceral pain: alleviates spasm‑related abdominal discomfort.

• Metamizole sodium monohydrate exerts its effect by non‑selectively inhibiting cyclooxygenase enzymes, which decreases synthesis of prostaglandins involved in pain and fever pathways. The reduction of peripheral prostaglandin levels, together with central analgesic and spasmolytic actions that are not fully elucidated, contributes to its antipyretic and analgesic properties. Additionally, the compound may modulate central nociceptive transmission, enhancing its overall analgesic effect.

Metamizol Kalceks may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site reactions: pain, redness, or swelling at the administration site.
• Transient hypotension: temporary drop in blood pressure shortly after injection.
• Nausea or vomiting: mild gastrointestinal upset.
• Dizziness or headache: occasional central nervous system symptoms.
• Mild leukopenia: slight decrease in white blood cell count.
• Flushing: transient redness of skin.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction of white blood cells, potentially life‑threatening.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Anaphylactic shock: acute allergic response requiring emergency care.
• Hepatic dysfunction: rare liver enzyme elevations.
• Acute renal failure: rare kidney impairment.

• When using Metamizol Kalceks, clinicians should observe several precautions to minimize risk.
• Patient assessment: evaluate for history of blood dyscrasias or hypersensitivity before administration.
• Monitoring: perform regular complete blood counts during prolonged therapy to detect agranulocytosis early.
• Concomitant drugs: avoid use with other myelosuppressive agents unless clinically justified.
• Renal/hepatic function: adjust use in patients with impaired kidney or liver function.
• Pregnancy and lactation: use only if potential benefit outweighs unknown risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metamizol Kalceks can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants: may enhance bleeding risk, requiring close monitoring.
• Other pyrazolones or NSAIDs: increase risk of agranulocytosis and gastrointestinal toxicity.
• Immunosuppressants: combined myelosuppression can be hazardous.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or diuretics: potential additive hypotensive effect.
• Antihypertensive agents: may require dose adjustment due to blood pressure changes.
• Drugs affecting liver enzymes: may alter metabolism of metamizole.